XLO earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.54. Updated 2026-07-23.
Xilio Therapeutics (XLO) Research Hub
Xilio Therapeutics (XLO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.93 USD (-0.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.54, market cap 0.06B. This hub links to the full technical, earnings and options research available for XLO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.93 USD (-0.45%) |
| 52-week range | 7.99 USD – 9.9 USD |
| Trend regime | Range |
| 14-day RSI | 42.6 (Bearish) |
| Trailing P/E | -1.54 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for XLO
Covered Call on XLO: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XLO: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XLO: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
XLO technical analysis: range, last 8.93 USD, RSI 42.6, 52w range 7.99 USD–9.9 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is XLO in?
Xilio Therapeutics (XLO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is XLO in an uptrend or downtrend?
As of 2026-09-11, XLO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XLO's trailing P/E ratio?
XLO's trailing P/E is -1.54, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does XLO next report earnings?
XLO is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.59 USD.